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The most frequent ultimate cause of death is myocardial arrest. In many cases this is due to myocardial hypoxia, generally
arising from failure of the coronary macro- and microcirculation to deliver enough oxygenated red cells to the cardiomyocytes.
The principle reason for this is occlusive thrombosis, either by isolated circulating thrombi, or by rupture of upstream plaque.
However, an additionally serious pathology causing potentially fatal stress to the heart is extra-cardiac disease, such as pulmonary
hypertension. A primary cause of the latter is pulmonary embolus, considered to be a venous thromboembolism. Whilst the
thrombotic scenario has for decades been the dominating paradigm in cardiovascular disease, these issues have, until recently,
been infrequently considered in cancer. However, there is now a developing view that cancer is also a thrombotic disease, and
notablyadiseasepredominantlyofthevenouscirculation,manifestingasdeep veinthrombosisandpulmonaryembolism.Indeed,
for many, a venous thromboembolism is one of the ﬁrst symptoms of a developing cancer. Furthermore, many of the standard
chemotherapies in cancer are prothrombotic. Accordingly, thromboprophylaxis in cancer with heparins or oral anticoagulation
(such as Warfarin), especially in high risk groups (such as those who are immobile and on high dose chemotherapy), may be an
important therapy. The objective of this communicationis to summarisecurrent views on the epidemiology and pathophysiology
of arterial and venous thrombosis in cancer.
1.Introduction
The greater part of human mortality and morbidity (cer-
tainly in the developed world) focuses on cardiovascular
disease and its risk factors, cancer, and connective tissue
disease [1]. The pathophysiology of cardiovascular disease
(endothelial damage leading to hypertension and thrombo-
sis) is established [2], whilst those subjects with connective
tissue disease (generally inﬂammatory) are also at risk of
possible life-terminating atherothrombosis [3]. A relation-
ship between cancer and thrombosis has been recognised
for almost 150 years, and each year brings additional data
that conﬁrms this association [4, 5]. Furthermore, the
large proportion of terminal events in neoplastic diseases
are thrombotic, leading to the hypothesis that cancer is
a prothrombotic disease [6–9]. However, such thromboses
may occur in arteries and/or veins, and many authorities
fail to diﬀerentiate between these two circulations, generally
focusing on venous thromboembolism (VTE). Nevertheless,
of PubMed citations of works on arterial and venous
thrombosis, approximately 25% are to arterial thrombosis.
An additional aspect of thrombosis and cancer is the
inevitably adverse eﬀect of chemotherapy (often anti-neo-
plastic and cytotoxic) in promoting thrombosis [8, 9].
Although there are isolated reports where hypercoagulability
and thrombosis closely follows chemotherapy [10, 11],
guidelines advocating prophylactic anticoagulation therapy
in the para-antineoplastic drug setting are becoming avail-
able. Indeed, one study named thromboembolism and in-
fection as leading precise causes of death in cancer patients
on chemotherapy [12].
The objective of this paper is to summarise potential
pathophysiological mechanisms to explain this relationship,
and to update facets of both arterial and venous thrombosis
in various cancers. To achieve this aim, on-line search
engines such as PubMed and Medline were probed using key2 Cardiology Research and Practice
words cancer, arterial thrombosis, venous thrombosis, and
anticoagulation. Whilst acknowledging advances brought by
tissue culture and animal models, the paper will focus on
human disease.
2.The Pathophysiologyof Thrombosis
Perhaps the oldest and most dominant theory of the patho-
physiology of thrombosis is that of Virchow, which has three
separate but overlapping parts: the contents of the blood,
the blood vessel wall, and blood ﬂow [13]. We currently
interpret this triad in terms of, respectively, platelets and
coagulationfactors(withminorrolesforredandwhiteblood
cells), the endothelium, and blood turbulence (as may be
present at valves and at bifurcations) and venostasis [14].
Certainly, however, these principles are as equally applicable
to arterial thromboses and to venous thromboses, and also
to cancer (Table 1). Indeed, patients with various cancers
frequently demonstrate abnormalities in each component
of Virchow’s triad, leading to a prothrombotic or hyper-
coagulable state. The mechanisms are likely to be multiple
and, probably, synergistic. For example, tumour cells may
be directly prothrombotic, inducing thrombin generation,
whilst normal host tissues may stimulate (or be stimulated
to) prothrombotic activity as a secondary response to
the cancer. However, dissecting the exact mechanisms is
frustrated by comorbidity and treatment eﬀects, such as bed
rest, infection, surgery, and drugs. Nevertheless, Virchow’s
triad also gives us the opportunity to dissect and identify
diﬀerent aspects of the causes of thrombosis.
2.1. The Contents of the Blood: Cells. Pathologists focus on
cells and on plasma molecules. The former clearly centre
on the platelet, although there are potential roles (if only
minor) for white blood cells and red blood cells, the latter
as ADP donors [15, 16]. Examples of platelet (hyper)activity
in cancer include reduced life span in myeloma, reduced
sensitivity toprostacyclinin endometrial,and cervicalcancer
[17, 18], with increased aggregability and higher levels of
platelet speciﬁc products soluble P-selectin, platelet factor 4,
thrombospondin and beta-thromboglobulin in lung, breast,
prostate,ovarian,andothercancers[19–26].Theseandother
ﬁndings support the general hypothesis of altered platelet
activity in cancer, especially in metastatic disease [27–
29]. Furthermore, it has been suggested that inappropriate
platelet activity promotes metastases [30, 31].
There are several plausible theories as to the causes of
this excess platelet activity. Cancer cells may activate platelets
in vitro by contact, by releasing platelet stimulators such
as ADP and thromboxane A2, and by generating thrombin
through theactivity ofthe tumour-associated procoagulants.
Increased von Willebrand factor, ristocetin cofactor, and
enhanced ADP-induced platelet aggregation have all been
demonstrated [32–36], and all these mechanism may pro-
mote thrombosis. However, in at least one clinical setting,
the true value of this has been questioned, as Canobbio et
al. [37] found that hypercoagulability was more likely to
be related to coagulation than to the expected increase in
Table 1: Virchow’s triad in cancer.
Abnormal blood ﬂow
(i) Increased plasma viscosity [114, 115]
(ii) Increased stasis due to immobility (e.g., being
bed-bound, in a wheelchair)
Abnormal blood constituents
(i) Increased platelet activation and aggregability, for
example, increased soluble P selectin, beta
thromboglobulin [15–51]
(ii) Loss of haemostasiswith increase in
procoagulants for example, increased ﬁbrinogen,
cancer procoagulant, PAI-1 [66–89]
Abnormal blood vessel wall
(i) Damaged or dysfunctional endothelium (e.g.,
increased soluble E selectin, increased soluble
thrombomodulin, possibly also related to
chemotherapy) [95–97]
(ii) Loss of anticoagulant nature and therefore
acquisition of a procoagulant nature (e.g., increased
von Willebrand factor, tissue factor, reduced tPA,
possibly also related to chemotherapy) [83, 93, 94]
(iii) Angiogenesis (altered release of, and response
to, growth factors) [101–107]
platelet aggregability. Nevertheless, there are several calls for
antiplatelet therapy in cancer [38–40], although concerns
have been aired [41].
A rapidly expanding area is that of microparticles
[42, 43]. Increased numbers of platelet microparticles have
been described in gastric, colon, and breast cancer [44–
46]. Interest in platelet microparticles follows a number of
themes; in the promotion of angiogenesis and metastases
[46–48], in the promotion of thrombosis (such as by bearing
tissue factor and phospholipids, thus providing a platform
for thrombosis) [45, 49, 50], and in the promotion of inva-
siveness[51].Thetumouritselfmayalsoshedmicroparticles,
and these too may be prothrombotic [52–54].
Monocytes may also be involved in cancer [55]. Early
work suggested a role in an immunological response to
neoplasia [56, 57], and although this persists, a more recent
view linking monocytes to coagulation has been introduced,
based on their ability to express tissue factor [58–61].
However, other mechanisms may also be important, such as
the delivery of cytokines and a role in angiogenesis [62, 63]
and there are also reports of the procoagulant activity of
monocytemicroparticles[64],and also ofcross-talk between
the monocyte and the platelet [65], all of which have the
p o t e n t i a lt op r o m o t et h r o m b o s i s .
2.2. The Contents of the Blood: Soluble Plasma Molecules.
There is also considerable evidence which implicates soluble
coagulation factors in cancer-related thrombosis [66]. The
normal clotting-ﬁbrinolytic system of haemostasis involves
a ﬁne balance between the activation and inhibition of
platelets, procoagulant factors, anticoagulant factors, and
ﬁbrinolytic factors [67]. This can easily be disrupted as
tumour cells can, for example, activate the coagulationCardiology Research and Practice 3
system directly through interactions with the clotting and
ﬁbrinolytic systems to generate thrombin [68]. The delicate
balancebetween thecoagulation and ﬁbrinolyticsystems can
easily shift to induce a prothrombotic state, perhaps via an
excess of procoagulant proteins such as tissue factor, ﬁb-
rinogen and plasminogen activator inhibitor (PAI-1), and/or
deﬁciencies in other molecules, such as anti-thrombin,
Proteins C and S, and tissue plasminogen activator (tPA)
[67, 69]. However, perhaps the greater part of the literature
in this area considers tissue factor and cancer procoagulant.
Tissue factorisprimary initiatorofcoagulation.Forming
a complex with factor VII to activate factors X and IX, it is
produced by monocytes and the endothelium [59]a n di s
functional both at the surface of the cell and as a soluble
component of plasma [70, 71]. Thus inv i v oexpression of
tissue factor, either by tumour and/or “normal” cells, and
soluble tissue factor has been implicated in intratumoral and
systemic activation of blood coagulation via the extrinsic
pathway, as well as in tumour growth and dissemination
[72–75].
Cancer procoagulant is a cysteine proteinase growth
factor that is a calcium-dependent, Mn2+ stimulated enzyme
[76]. Unlike tissue factor, cancer procoagulant is a direct
a c t i v a t o ro ff a c t o rXw i t h o u tt h en e e df o rf a c t o rV I Ia n d
is found in malignant and fetal tissue, but not in normally
diﬀerentiated tissue [77]. Concerns that at least some part
of cancer procoagulant activity could be accounted for by
contaminating tissue factors seem to have been dispelled
[78]. In the presence of factor V, cancer procoagulant
may further enhance thrombin generation by up to 3-fold.
Increased cancer procoagulant levels have been reported
in patients with acute promyelocytic leukemia, malignant
melanoma, and cancers of the colon, breast, lung, and
kidney, and there is in vitro evidence that it may also be
involved in metastatic potential [79–82]
Numerous other proteins within the coagulation cascade
have been shown to be abnormally elevated, often in associ-
ation with a fall in the activity of “anticoagulant” factors. For
example, reduced levels of t-PA activity have been described
in patients with gastrointestinal cancer [83], whilst that of
PAI-1and otherinhibitoryfactors oftheﬁbrinolyticpathway
canbe elevated[84]. Bothof these factors are likelyto lead to
a prothrombotic or hypercoagulable state. In addition, there
are decreases in other anticoagulant factors, including anti-
thrombin and resistance to activated protein C.The evidence
of this on-going underlying state of heightened coagulation
in cancer is clear from the numerous studies looking at
levels of ﬁbrinogen and other indices of ﬁbrin turnover
including D-dimers [71, 85–89]. Increased levelsof the latter
reﬂect increased clot turnover (thrombolysis) which in turn
implies increased thrombotic load, as is present in actual
venothromboembolic disease, and levels of D-dimers are
part of the clinical assessment of subjects with suspected
venothromboembolism [90]. However, there is evidence of
v e r yh i g hD - d i m e rl e v e l si np a t i e n t sw i t hc a n c e rw h od o
not have VTE. This suggests that elevated D-dimer levels
in patients with VTE and malignancy are not solely due
to presence of thrombus. Knowlson et al. suggest that high
D-dimer levels in malignancy are likely to reﬂect the biology
of the underlying tumour, with higher levels observed in
breast, prostate, and bowel cancers [91].
2.3. Abnormalities of Vessel Wall. The role of endothelium
in mediating the prothrombotic or hypercoagulable state is
well-known, and disturbances in vascular function may be
assessed by changes in plasma levels of certain molecules
such as von Willebrand factor (vWf), soluble thrombo-
modulin, and soluble E-selectin [92]. Increased vWf has
long been described in cancer [93, 94], and this may
not only indicate endothelial damage but also seem likely
to contribute to thrombosis by promoting platelet-platelet
and platelet-subendothelium adhesion, as may increased
ﬁbrinogen [92–94].Similarly, increased soluble(i.e.,plasma)
thrombomodulin (as in present in cancer [95]) may account
for the loss of anticoagulant membrane thrombomodulin
at the endothelial surface [96]. Thus changes in vWf and
thrombomodulin are likely to promote coagulopathy and
thus provide a paradigm for thrombosis in cancer. Increased
soluble E selectin in cancer may simply be a marker of
endothelial disturbance with no direct implications for
hameostasis [97]
Endothelial cells may become prothrombotic under the
inﬂuenceofinﬂammatory cytokinessuch astumour necrosis
factor (TNF)and interleukin(IL)-1.Suchcytokinessuppress
endothelial ﬁbrinolytic activity, increase endothelial cell
production of IL-1 and vWf, and downregulate thrombo-
modulin expression that diminishes the activation of the
anticoagulant protein C [98]. Cytokinessuch as TNF and IL-
1,oftenincreased incancer[99],alsoincrease theendothelial
expression of E selectin, platelet activating factors, and tissue
factor [98, 100]. Thus hypoxia and/or cytokine-mediated
endothelial cell damage or dysfunction has the potential
to further contribute to hypercoagulable state. A damaged
endothelium may also present less of a challenge to a
metastatic tumour cell seeking to penetrate the vessel wall.
Solid tumours growing outside of the blood vasculature may
alsoincrease thepermeabilityofthemicrovasculature,allow-
ingﬁbrinogenandotherplasma-clottingproteinstoleakinto
the extravascular space where procoagulants associated with
tumourcells orwith benignstromal cellscaninitiate clotting
and subsequent ﬁbrin deposition [100].
Several ﬁndings suggest a link between angiogenesis
and thrombosis. One of the oldest provides a rationale
for a role for platelet derived growth factor (PDGF), and
plateletderivedendothelialgrowthfactor, possiblyshedfrom
para-neoplastic thrombus, in neovascularisation [101, 102].
Others have localised tissue factor expression in the vascular
endothelium of breast cancer tissue, which strongly correlate
withtheinitiationofangiogenesis,hencesuggestingafurther
possible link between the prothrombotic states and angio-
genesis in these patients [103, 104]. Tissue factor expression
has also been shown to correlate positively with microvessel
density and the expression of the angiogenic modulator,
vascular endothelial growth factor (VEGF) [105]. Interest-
ingly, VEGF induces hyperpermeability by a direct action on
the endothelium [106] and (unlike basic ﬁbroblast growth
factor) promotes platelet activation and adhesion [107]4 Cardiology Research and Practice
although both in vitro. An additional factor is the possibility
that platelet-derived VEGF and other angiogenic molecules
may be important in malignancy [108–110].
2.4.Abnormalities ofBloodFlow. There seems tolittle ﬁrm in
vivo data directly implicating this third aspect of Virchow’s
triad in the pathogenesis of human cancer, although imaging
studies of blood ﬂow may be a useful investigation [111].
What would seem to be a likely mechanism in cardiovascular
disease [112] may not be the case in neoplasia, although
there are in vitro data [113]. Nevertheless, blood viscosity
at both high and low rates of shear [114], and a yield
stress index measured preoperatively in cancer patients,
has been correlated with the incidence of post-operative
DVT [115]. The possibility arises that abnormal blood
vessel formation (perhaps related to cancer angiogenesis and
factors promoting this) may cause ﬂow disturbance.
3.The Effectsof Therapyand Stagingon
theRiskofThrombosis
Apart from what may be described as the “natural” patho-
physiology, as exempliﬁed by Virchow’s triad, many inter-
ventions to treat cancer are prothrombotic. There is ample
evidence that numerous chemotherapeutic agents, including
methotrexate, cisplatin and etoposide, as well as hormonal
therapies used in cancer, such as medroxyprogesterone
acetate and thalidomide, have all been implicated as risk
factors for thromboembolism [116–121]. Other interven-
tions such as central venous catheter placements, surgery,
sepsis, and venous stasis from immobility also contribute
to risk of thromboembolism [122], although some of
this extra risk may be due to local inﬂammation and/or
infection [123]. Furthermore, the general principle that
chemotherapy induces thrombosis extends to nonmalignant
diseases such as lupus [124]. An exact position for a role of
radiotherapy in promoting thrombosis is marred in many
studies by combination chemotherapy. Nevertheless, there
are instances where radiotherapy does indeed increase the
risk of thrombosis but may also damage the endothelium,
and collectively, these issues prompt the need for pro-active
anticoagulant therapy in high risk groups [121, 125–128].
Levels of plasma markers of thrombin and plasmin
generation have been related to staging, prognosis and
interventioninpatientswithvariouscancers,includingthose
of the cervix, lung, ovary, prostate, and breast. For example,
inthestudybyGadduccietal.[128], levelsofprothrombotic
indices were signiﬁcantly raised in patients with cervical
cancer,andrelatedtosurgical-pathologicalstageandtumour
size, but not to histologic type. Similarly, several studies have
shown an association between activation of blood coagula-
tion and ﬁbrinolysis with distant metastasis, histologic type
of tumour and response to chemotherapy; indeed, gross
abnormalities of prothrombotic indices might even be a
signofunfavourableprognosisincertainpatients[129–131].
However,othersfailed to noteany changesin preoperativeor
sequential measurements up to 9 months postoperatively of
ﬁbrinopeptide A, ﬁbrin fragment B beta 15–42, ﬁbrinogen
and serum ﬁbrin degradation products that correlated with
early recurrent breast cancer, although some markers were
higher in patients with oestrogen receptor positive tumours,
orincreased postoperatively,largely because of anincrease in
patients with oestrogen receptor negative tumours [132].
4.ArterialThrombosisinCancer
As discussed, there is considerably more data on venous
thrombosis than for arterial thrombosis in cancer. Never-
theless, thrombosis in arteries has long been recognised,
although the exact mechanisms, in many cases, remain
obscure [133–135]. However, increased levels of coagulation
molecules, concurrent disease (such as endocarditis), use
of growth factors, and cytotoxic chemotherapy may all
precipitate thrombosis [136–140]. A potential mechanism
for the latter may be endothelial damage with the loss
of its natural anticoagulant nature and acquisition of a
procoagulant proﬁle [141]. However, the fact that a large
proportion of these studies are case reports underlines the
rarity of arterial thrombosis in cancer [138–141]. Ross et al.
provided additional possible pathogenic mechanisms related
to atherosclerosis whilst Lowe summarised common risk
factors for arterial and venous thrombosis [142, 143].
5.Prophylaxisand Treatment
A detailed discussion of the prevention and treatment
of thromboembolism in cancer is beyond the scope of
this paper, although at least one commentator refers to
treatment of arterial cancer with anticoagulants [134].
Nevertheless, primary prevention of VTE, possibly by
vitamin K antagonists (VKAs) should be considered for
“high-risk” cancer patients during and immediately after
chemotherapy, when long-term indwelling central venous
catheters are placed, during prolonged immobilization from
any cause, and following surgical interventions [118, 127].
For example, in cancer patients going for general surgery
withoutprophylaxis,theincidenceofdeepveinthrombosisis
approximately 29% as compared to 19% of patients without
cancer[144].ThusapossiblerouteforthepreventionofVTE
in high-risk cancer patients undergoing surgery or adjuvant
chemotherapy may be the use of long-term low-intensity
anticoagulation [145]. However, there are concerns of the
safety of VKA anticoagulants in cancer as these may cause an
increase in all bleeding, major bleeding, and minor bleeding
compared to patients free of cancer [146]. A meta-analysis
found no evidence that warrants treatment with VKAs with
the aim of improving survival [147].
These and other data suggest that, for many, low molec-
ular weight heparins (LMWHs) will be the therapy of choice
[155], not merely because of a reduced rate of complications
such as haemorrhage [127], but also because it improves
o v e r a l ls u r v i v a l[ 156] .L e ee ta l .r e p o r t e dar a t eo fr e c u r r e n t
VTE of 17% in patients on VKA anticoagulants compared to
9% in those on an LMWH [157], and later noted that the use
of a LMWH relative to coumarin derivatives was associated
with improved survival in patients with solid tumours whoCardiology Research and Practice 5
Table 2: Potential treatments of patients with cancer.
Patient group Role of VTE prophylaxis
Hospitalised Consider UFH, LMWH, or fondaparinux (strongly consider if bedridden
and active cancer)
Ambulatory patients free of VTE but receiving systemic
chemotherapy
Routine prophylaxis not recommended (conﬂicting data, risk of
haemorrhage, low risk of VTE)
Patients with myeloma free of VTE on thalidomide or
lenalidomide plus chemotherapy or dexamethasone LMWH or low dose warfarin (target INR 1.5)
About to undergo surgery
Consider UFH, LMWH, or fondaparinux for 7–10 days. Consider extended
(4 week) prophylaxis with LMWH after major surgery, obesity, and a
history of VTE.
Those with established VTE to prevent recurrence LMWH 5–10 days in the initial phase, then long-term treatment (6
months) with LMWH preferred to oral anticoagulation.
Active cancer (metastatic disease, continuing
chemotherapy). Indeﬁnite anticoagulation should be considered
Table amended from [148]. See also [149, 150]. UFH: unfractionated heparin. LMWH: low molecular weight heparin. VTE: venous thromboembolism.
Table 3: Evidence that not all cancers are associated with the same risk of VTE.
Rank Reference [151] Reference [152] Reference [153] Reference [154]
1 Ovary Pancreas Kidney Bone
2 Pancreas Head/neck Pancreas Ovary
3 Liver CNS Gastric Brain
4 Blood Upper GI Brain Pancreas
5 Brain Endocrine Lymph nodes
6K i d n e y L u n g C e r v i x
7 Lung Colorectal Stomach
See particular references for ﬁne details.CNS: central nervous system;GI: gastrointestinal. A model for predicting chemotherapy-associatedVTE places more
emphasis on cancers of the stomach and pancreas than on cancers of the lung, bladder, testes, lymph nodes, and femalereproductive system [12].
did not have metastatic disease at the time of an acute VTE
[158]. Indeed, a recent international guideline on the use
of anticoagulants in cancer for prophylaxis and treatment
is dominated by LMWHs [148]( Table 2). Although use
of LMWH compared to unfractionated heparin confers a
survival advantage, the precise role of LMWHs in survival
in those free of VTE is unclear but demands careful
prospective analysis [159]. But whatever treatment mode is
adopted, its use is likely to be long-term in high risk groups
[148, 149, 160].
6.Conclusion
It has been long been recognised that cancer confers a
prothrombotic or hypercoagulable state, most likely through
an altered balance between the coagulation and ﬁbrinolytic
systems [161]. More recently it is clear that this risk can be
relatedtolong-termprognosisandtreatment [162–164],and
hospitalisation for a VTE is a risk factor for a second cancer
[165]. Whilst most thromboses in cancer are venous, arterial
thrombosis is common, possible because the two share many
risk factors [140]. Indeed, patients with an unprovoked
VTE are at increased risk of an arterial thrombosis [166].
Procoagulants such as tissue factor are expressed by many
tumours [73, 75, 104], and although platelet turnover and
activity are also increased, it is unclear whether or not
platelets themselves and/or their products actively promote
thrombosis [167, 168], although a high platelet count is a
risk factor for chemotherapy-associated thrombosis [169].
Risk factors for VTE whilst on chemotherapy include
presence of metastases, high leukocyte count and platin-
based chemotherapy [170]. There is also a growing view that
some cancers are more prothrombotic than others (Table 3).
Although a ﬂawed analysis, a crude summation of this table
suggests that pancreatic cancer and ovarian cancer are most
likely to provoke a VTE.
Although guidelines and a consensus statement for
anticoagulant treatment areavailable[148–150,171],further
work is needed to elucidate the mechanism (s) leading to the
prothrombotic state in cancer, the potential prognostic and
treatment implications, and thepossible valueofquantifying
indices of hypercoagulability in routine clinical practice.
Carefullydesignedstudieswiththeappropriatemethodology
to establish the predictive value of various abnormalities of
the prothrombotic or hypercoagulable state are needed. In
this respect the development of a risk factor score, which
includes leukocyte count, platelet count, and levels of tissue
factor, soluble P-selectin and D-dimer, points a possible way6 Cardiology Research and Practice
forward in identifying those at greatest risk of thrombosis,
possibly due to chemotherapy, and who therefore warrant
treatment [172–174]. In support of this hypothesis is data
showed the value of adding soluble P-selectin and D-dimer
to a risk calculator [175].
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